|
|
|
Volumn 4, Issue 1, 1996, Pages 61-72
|
|
Liver III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DIMEG;
GADOBENIC ACID;
GADOLINIUM PENTETATE;
SHL 569 B;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
CONTRAST ENHANCEMENT;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG SAFETY;
HUMAN;
LIVER CELL CARCINOMA;
LIVER METASTASIS;
MULTICENTER STUDY;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
REVIEW;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
CONTRAST MEDIA;
FEMALE;
GADOLINIUM;
GADOLINIUM DTPA;
HUMANS;
LIVER;
LIVER DISEASES;
LIVER NEOPLASMS;
MAGNETIC RESONANCE IMAGING;
MALE;
MEGLUMINE;
MULTICENTER STUDIES;
ORGANOMETALLIC COMPOUNDS;
PENTETIC ACID;
SAFETY;
|
|
EID: 0029925851
PISSN: 10649689
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (43)
|
|
References (0)
|
